Log in

NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

$51.51
-0.50 (-0.96 %)
(As of 02/17/2020 03:56 AM ET)
Add
Today's Range
$51.35
Now: $51.51
$52.99
50-Day Range
$45.32
MA: $49.93
$53.81
52-Week Range
$28.36
Now: $51.51
$68.94
Volume534,602 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AGIO
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees482
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.


Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to the consensus estimate of $33.72 million. Agios Pharmaceuticals's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.58) EPS. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 brokerages have issued 1 year target prices for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $79.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $64.56 in the next year. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

Media headlines about AGIO stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Agios Pharmaceuticals.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV) and Micron Technology (MU).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), State Street Corp (3.20%), First Trust Advisors LP (2.60%), Farallon Capital Management LLC (2.12%), ArrowMark Colorado Holdings LLC (1.88%) and Perceptive Advisors LLC (1.53%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Casdin Capital LLC, Handelsbanken Fonder AB, Rhenman & Partners Asset Management AB, New York State Common Retirement Fund, Rafferty Asset Management LLC, Alyeska Investment Group L.P. and Bank of Montreal Can. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Perceptive Advisors LLC, First Trust Advisors LP, Bank of America Corp DE, Marshall Wace LLP, UBS Asset Management Americas Inc., Cadian Capital Management LP and ArrowMark Colorado Holdings LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $51.51.


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  422 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  777
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel